MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that its telomerase inhibitor cancer drug, GRN163L, is active against cancer stem cells from multiple myeloma patients, according to data presented at the American Society of Hematology 48th Annual Meeting in Orlando, Fla.
